source
- Sofinnova closes second crossover fund at €725M for late-stage European biotechsSofinnova Partners has secured €725 million ($815 million) for its second crossover fund, which it said would fill the financing gap for late-stage European biopharma and medtech companies. Europe…Endpoints · 1h ago↗ source
- FDA rejects Summit and Akeso's ivonescimab for narrow lung cancerThe U.S. Food and Drug Administration has turned down ivonescimab, a new cancer therapy being developed by Summit Therapeutics and Akeso, for use in a specific type of lung cancer. Analysts had la…